Evermay Wealth Management LLC bought a new stake in shares of Bristol-Myers Squibb (NYSE:BMY) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 3,789 shares of the biopharmaceutical company’s stock, valued at approximately $232,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BMY. NuWave Investment Management LLC bought a new position in Bristol-Myers Squibb in the 4th quarter valued at $119,000. Wealthstreet Investment Advisors LLC bought a new position in Bristol-Myers Squibb in the 4th quarter valued at $10,654,000. South Texas Money Management Ltd. grew its position in Bristol-Myers Squibb by 0.9% in the 4th quarter. South Texas Money Management Ltd. now owns 680,454 shares of the biopharmaceutical company’s stock valued at $41,698,000 after acquiring an additional 6,334 shares during the last quarter. LS Investment Advisors LLC grew its position in Bristol-Myers Squibb by 4.6% in the 4th quarter. LS Investment Advisors LLC now owns 94,246 shares of the biopharmaceutical company’s stock valued at $5,775,000 after acquiring an additional 4,130 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its position in Bristol-Myers Squibb by 5.9% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 130,529 shares of the biopharmaceutical company’s stock valued at $7,998,000 after acquiring an additional 7,214 shares during the last quarter. 71.51% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NYSE BMY traded down $1.43 during mid-day trading on Friday, reaching $60.88. 6,462,049 shares of the company were exchanged, compared to its average volume of 5,604,834. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.43. The stock has a market capitalization of $99,391.66, a P/E ratio of 20.23, a price-to-earnings-growth ratio of 1.58 and a beta of 0.96. Bristol-Myers Squibb has a 1 year low of $51.56 and a 1 year high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. The firm had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The firm’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.63 EPS. equities research analysts anticipate that Bristol-Myers Squibb will post 3.22 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Investors of record on Friday, April 6th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.63%. The ex-dividend date of this dividend is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 53.16%.
BMY has been the topic of several research analyst reports. Argus reaffirmed a “buy” rating and issued a $66.43 price objective (down previously from $75.00) on shares of Bristol-Myers Squibb in a research report on Wednesday, March 21st. Vetr downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price target on the stock. in a research report on Tuesday, January 16th. Zacks Investment Research raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Friday, January 19th. JPMorgan Chase set a $75.00 price target on Bristol-Myers Squibb and gave the stock an “overweight” rating in a research report on Tuesday, March 20th. Finally, Credit Suisse Group set a $62.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, January 22nd. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $66.68.
TRADEMARK VIOLATION NOTICE: “3,789 Shares in Bristol-Myers Squibb (BMY) Purchased by Evermay Wealth Management LLC” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/08/evermay-wealth-management-llc-buys-new-stake-in-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.